Relationship between left ventricular hypertrophy diagnosed by Peguero-Lo-Presti index and recurrence after radiofrequency catheter ablation of paroxysmal atrial fibrillation

doi:10.11958/20230627

Abstract

Abstract:

Objective To investigate the relationship between left ventricular hypertrophy (LVH) diagnosed by Peguero-Lo-Presti index and recurrence of paroxysmal atrial fibrillation (AF) after radiofrequency ablation. Methods A total of 652 patients with paroxysmal atrial fibrillation who underwent radiofrequency ablation were selected. According to Peguero-Lo-Presti index, patients were divided into the LVH group (167 cases) and the normal left ventricle group (485 cases). Baseline data were collected, and regular follow-up was performed at 3, 6 and 12 months after radiofrequency catheter ablation. The recurrence of AF was assessed. Kaplan-Meier survival curve was used to analyze the recurrence rate of AF in the two groups. Cox proportional hazard model was used to assess risk factors for recurrent atrial fibrillation. Results The median follow-up time was 20.5 (15.0, 26.0) months. A total of 155 patients (23.8%) developed recurrence of AF, including 95 patients in the LVH group and 60 patients in the LVN group. The recurrence rate without AF was significantly lower in the LVH group than that in the LVN group (64.1% vs. 80.4%, Log-rank χ²=26.361, P<0.01). After adjusting for age, sex, body mass index, hypertension, diabetes, coronary heart disease, cardiac dysfunction, left anteroposterior and posterior atrial diameter, left ventricular end-diastolic diameter, and left ventricular ejection fraction, LVH diagnosed by Peguero-Lo-Presti index was still a risk factor for recurrent AF [HR (95%CI) : 2.359 (1.663-3.345), P<0.01]. Conclusion In patients with paroxysmal AF, LVH diagnosed by Peguero-Lo-Presti index is a risk factor of AF recurrence after radiofrequency catheter ablation.

Key words: hypertrophy, left ventricular, atrial fibrillation, radiofrequency ablation, recurrence, Peguero-Lo-Presti index

CLC Number:

R541.75

Figures/Tables 3

References 29

[1]	LIPPI G, SANCHIS-GOMAR F, CERVELLIN G. Global epidemiology of atrial fibrillation: An increasing epidemic and public health challenge[J]. Int J Stroke, 2021, 16(2):217-221. doi:10.1177/1747493019897870.
[2]	黄从新, 张澍, 黄德嘉, 等. 心房颤动:目前的认识和治疗的建议-2018[J]. 中国心脏起搏与心电生理杂志, 2018, 32(4):315-368.
	HUANG C X, ZHANG S, HUANG D J, et al. Atrial fibrillation:Current understanding and recommendations for Treatment 2018[J]. Chinese Journal of Cardiac Pacing and Electrophysiology, 2018, 32(4):315-368. doi:10.13333/j.cnki.cjcpe.2018.04.001.
[3]	TANAKA F, KOMI R, NAKAMURA M, et al. Additional prognostic value of electrocardiographic left ventricular hypertrophy in traditional cardiovascular risk assessments in chronic kidney disease[J]. J Hypertens, 2020, 38(6):1149-1157. doi:10.1097/HJH.0000000000002394.
[4]	BAKHTIARI F, DAVARMOIN G, GHAFFARI S, et al. Electrocardiographic left ventricular hypertrophy is not associated with increased in-hospital adverse events in patients with first Non-ST segment elevation myocardial infarction:A single center study[J]. Caspian J Intern Med, 2019, 10(3):289-294. doi:10.22088/cjim.10.3.289.
[5]	HANCOCK E W, DEAL B J, MIRVIS D M, et al. AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram:part V:electrocardiogram changes associated with cardiac chamber hypertrophy:a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee,Council on Clinical Cardiology;the American College of Cardiology Foundation;and the Heart Rhythm Society:endorsed by the International Society for Computerized Electrocardiology[J]. Circulation, 2009, 119(10):e251-261. doi:10.1161/CIRCULATIONAHA.108.191097.
[6]	PEGUERO J G, LO PRESTI S, PEREZ J, et al. Electrocardiographic criteria for the diagnosis of left ventricular hypertrophy[J]. J Am Coll Cardiol, 2017, 69(13):1694-1703. doi:10.1016/j.jacc.2017.01.037.
[7]	张明龙, 杨文琦, 王晓东, 等. 左心室肥厚的心电图诊断新标准在中国人群中的诊断价值及其影响因素[J]. 心脏杂志, 2022, 34(2):178-182.
	ZHANG M L, YANG W Q, WANG X D, et al. Diagnostic efficacy and influencing factors of a new standard for diagnosis of left ventricular hypertrophy in Chinese population[J]. Chinese Heart Journal, 2022, 34(2):178-182. doi:10.12125/j.chj.202105003.
[8]	XIA Y, LI X F, LIU J, et al. The influence of metabolic syndrome on atrial fibrillation recurrence:five-year outcomes after a single cryoballoon ablation procedure[J]. J Geriatr Cardiol, 2021, 18(12):1019-1028. doi:10.11909/j.issn.1671-5411.2021.12.008.
[9]	贾朝旭, 蒋超, 卢尚欣, 等. 体重控制与超重及肥胖患者心房颤动射频消融术后复发的关系[J]. 中华心血管病杂志, 2019, 47(8):595-601.
	JIA C X, JIANG C, LU S X, et al. Association between weight control and recurrence of atrial fibrillation after catheter ablation in overweight and obese patients[J]. Chin J Cardiol, 2019, 47(8):595-601. doi:10.3760/cma.j.issn.0253?3758.2019.08.002.
[10]	FINK T, SCHLÜTER M, HEEGER C H, et al. Stand-alone pulmonary vein isolation versus pulmonary vein isolation with additional substrate modification as index ablation procedures in patients with persistent and long-standing persistent atrial fibrillation:the randomized alster-lost-af trial(ablation at st. georg hospital for long-standing persistent atrial fibrillation)[J]. Circ Arrhythm Electrophysiol, 2017, 10(7):e005114. doi:10.1161/CIRCEP.117.005114.
[11]	NAKAMURA T, HACHIYA H, YAGISHITA A, et al. The relationship between the profiles of SVC and sustainability of SVC fibrillation induced by provocative electrical stimulation[J]. Pacing Clin Electrophysiol, 2016, 39(4):352-360. doi:10.1111/pace.12814.
[12]	ANSELME F, SAVOURé A, CLéMENTY N, et al. Preventing atrial fibrillation by combined right isthmus ablation and cryoballoon pulmonary vein isolation in patients with typical atrial flutter:PAF-CRIOBLAF study[J]. J Arrhythm, 2021, 37(5):1303-1310. doi:10.1002/joa3.12626.
[13]	KUCK K H, BRUGADA J, FüRNKRANZ A, et al. Cryoballoon or radiofrequency ablation for paroxysmal atrial fibrillation[J]. N Engl J Med, 2016, 374(23):2235-2245. doi:10.1056/NEJMoa1602014.
[14]	MOHANTY S, DELLA ROCCA D G, GIANNI C, et al. Predictors of recurrent atrial fibrillation following catheter ablation[J]. Expert Rev Cardiovasc Ther, 2021, 19(3):237-246. doi:10.1080/14779072.2021.1892490.
[15]	LIU P, LV T, YANG Y, et al. Use of P wave indices to evaluate efficacy of catheter ablation and atrial fibrillation recurrence: a systematic review and meta-analysis[J]. J Interv Card Electrophysiol, 2022, 65(3):827-840. doi:10.1007/s10840-022-01147-7.
[16]	CUSPIDI C, SALA C, NEGRI F, et al. Prevalence of left-ventricular hypertrophy in hypertension: an updated review of echocardiographic studies[J]. J Hum Hypertens, 2012, 26(6):343-349. doi:10.1038/jhh.2011.104.
[17]	CUSPIDI C, FACCHETTI R, QUARTI-TREVANO F, et al. Incident left ventricular hypertrophy in masked hypertension[J]. Hypertension, 2019, 74(1):56-62. doi:10.1161/HYPERTENSIONAHA.119.12887.
[18]	JIANSHU C, QIONGYING W, YING P, et al. Association of free androgen index and sex hormone-binding globulin and left ventricular hypertrophy in postmenopausal hypertensive women[J]. J Clin Hypertens(Greenwich), 2021, 23(7):1413-1419. doi:10.1111/jch.14301.
[19]	VERDECCHIA P, REBOLDI G, GATTOBIGIO R, et al. Atrial fibrillation in hypertension:predictors and outcome[J]. Hypertension, 2003, 41(2):218-223. doi:10.1161/01.hyp.0000052830.02773.e4.
[20]	CHRISPIN J, JAIN A, SOLIMAN E Z, et al. Association of electrocardiographic and imaging surrogates of left ventricular hypertrophy with incident atrial fibrillation:MESA(Multi-Ethnic Study of Atherosclerosis)[J]. J Am Coll Cardiol, 2014, 63(19):2007-2013. doi:10.1016/j.jacc.2014.01.066.
[21]	VERDECCHIA P, REBOLDI G, DI PASQUALE G, et al. Prognostic usefulness of left ventricular hypertrophy by electrocardiography in patients with atrial fibrillation(from the Randomized Evaluation of Long-Term Anticoagulant Therapy Study)[J]. Am J Cardiol, 2014, 113(4):669-675. doi:10.1016/j.amjcard.2013.10.045.
[22]	ARO A L, CHUGH S S. Clinical diagnosis of electrical versus anatomic left ventricular hypertrophy:Prognostic and therapeutic implications[J]. Circ Arrhythm Electrophysiol, 2016, 9(4):e003629. doi:10.1161/CIRCEP.115.003629.
[23]	LI S N, WANG L, DONG J Z, et al. Electrocardiographic left ventricular hypertrophy predicts recurrence of atrial arrhythmias after catheter ablation of paroxysmal atrial fibrillation[J]. Clin Cardiol, 2018, 41(6):797-802. doi:10.1002/clc.22957.
[24]	王璐, 李松南, 董建增, 等. 左心室肥厚对合并高血压阵发性心房颤动患者射频消融术后复发的影响[J]. 中华心律失常学杂志, 2018, 22(5):412-418.
	WANG L, LI S N, DONG J Z, et al. Electrocardiographic left ventricular hypertrophy predicts recurrence of atrial arrhythmias after catheter ablation of paroxysmal atrial fibrillation with hypertension[J]. Chinese Journal of Cardiac Arrhythmias, 2018, 22(5):412-418. doi:10.3760/cma.j.issn.1007-6638.2018.05.009.
[25]	ZHU P, DAI Y, QIU J, et al. Prognostic implications of left ventricular geometry in coronary artery bypass grafting patients[J]. Quant Imaging Med Surg, 2020, 10(12):2274-2284. doi:10.21037/qims-19-926.
[26]	BADHEKA A O, SHAH N, GROVER P M, et al. Outcomes in atrial fibrillation patients with and without left ventricular hypertrophy when treated with a lenient rate-control or rhythm-control strategy[J]. Am J Cardiol, 2014, 113(7):1159-1165. doi:10.1016/j.amjcard.2013.12.021.
[27]	MEDI C, KALMAN J M, SPENCE S J, et al. Atrial electrical and structural changes associated with longstanding hypertension in humans:implications for the substrate for atrial fibrillation[J]. J Cardiovasc Electrophysiol, 2011, 22(12):1317-1324. doi:10.1111/j.1540-8167.2011.02125.x.
[28]	GUO D, YOUNG L, WU Y, et al. Increased late sodium current in left atrial myocytes of rabbits with left ventricular hypertrophy:its role in the genesis of atrial arrhythmias[J]. Am J Physiol Heart Circ Physiol, 2010, 298(5):H1375-1381. doi:10.1152/ajpheart.01145.2009.
[29]	PIERAGNOLI P, PAOLETTI PERINI A, RICCIARDI G, et al. Recurrences in the blanking period and 12-month success rate by continuous cardiac monitoring after cryoablation of paroxysmal and non-paroxysmal atrial fibrillation[J]. J Cardiovasc Electrophysiol, 2017, 28(6):625-633. doi:10.1111/jce.13190.

组别	n			年龄/岁				男性		BMI/（kg/m²）					高血压
LVN组	485			58.9±9.90				340（70.1）		25.9±3.56					277（57.1）
LVH组	167			59.7±9.93				94（56.3）		26.0±3.50					110（65.9）
t或χ²				0.893				10.040^＊＊		0.136					3.592
组别		糖尿病				冠心病			心功能不全				外周血管疾病
LVN组		99（20.4）				116（23.9）			64（13.2）				120（24.7）
LVH组		46（27.5）				53（31.7）			33（19.8）				43（25.7）
χ²		3.254				3.559			3.725				0.024
组别			卒中/TIA				NT-proBNP/（ng/L）				LAD/mm			LVEDD/mm
LVN组			85（17.5）				140.4（49.6，397.9）				39.0±5.18			47.2±4.86
LVH组			35（21.0）				228.4（55.0，756.7）				40.0±5.39			48.9±4.64
t、χ²或Z			0.759				2.755^＊＊				2.259^＊			4.116^＊＊
组别		LVEF			CHA₂DS₂-VASc评分/分							HASBLED评分/分
LVN组		0.63±0.05			2（1，3）							1（1，2）
LVH组		0.64±0.05			2（1，4）							2（1，2）
t或χ²		2.061^＊			0.144							1.007

组别	n			年龄/岁				男性		BMI/（kg/m²）					高血压
LVN组	485			58.9±9.90				340（70.1）		25.9±3.56					277（57.1）
LVH组	167			59.7±9.93				94（56.3）		26.0±3.50					110（65.9）
t或χ²				0.893				10.040^＊＊		0.136					3.592
组别		糖尿病				冠心病			心功能不全				外周血管疾病
LVN组		99（20.4）				116（23.9）			64（13.2）				120（24.7）
LVH组		46（27.5）				53（31.7）			33（19.8）				43（25.7）
χ²		3.254				3.559			3.725				0.024
组别			卒中/TIA				NT-proBNP/（ng/L）				LAD/mm			LVEDD/mm
LVN组			85（17.5）				140.4（49.6，397.9）				39.0±5.18			47.2±4.86
LVH组			35（21.0）				228.4（55.0，756.7）				40.0±5.39			48.9±4.64
t、χ²或Z			0.759				2.755^＊＊				2.259^＊			4.116^＊＊
组别		LVEF			CHA₂DS₂-VASc评分/分							HASBLED评分/分
LVN组		0.63±0.05			2（1，3）							1（1，2）
LVH组		0.64±0.05			2（1，4）							2（1，2）
t或χ²		2.061^＊			0.144							1.007

因素	β	SE	Wald χ²	P	HR（95% CI）
未校正	0.821	0.166	24.376	<0.001	2.288（1.652~3.169）
模型一	0.837	0.170	25.292	<0.001	2.328（1.670~3.247）
模型二	0.836	0.173	26.131	<0.001	2.329（1.661~3.265）
模型三	0.848	0.178	33.213	<0.001	2.359（1.663~3.345）

因素	β	SE	Wald χ²	P	HR（95% CI）
未校正	0.821	0.166	24.376	<0.001	2.288（1.652~3.169）
模型一	0.837	0.170	25.292	<0.001	2.328（1.670~3.247）
模型二	0.836	0.173	26.131	<0.001	2.329（1.661~3.265）
模型三	0.848	0.178	33.213	<0.001	2.359（1.663~3.345）